Navigation Links
tellic Launches drug360 Knowledge Graph to Unlock Genetic Insights from Biomedical Data

drug360 graph, a breakthrough knowledge graph product, has just been released by pharma artificial intelligence pioneer tellic. drug360 brings tellic’s expertise in biomedical language processing and machine learning to bear on biomedical big data. This new tool allows researchers to quickly uncover relationships between genes, diseases, variants, phenotypes, and other biomedical entities. Researchers and analysts can use drug360 graph to dramatically increase their efficiency searching multiple data sources and uncover valuable genetic knowledge supporting decisions around their pipelines.

“drug360 graph provides greater confidence around the crucial decisions researchers make regarding advancing drug candidates or abandoning them,” says Richard Wendell, tellic CEO. “Research shows that genetic evidence can double the chances of a clinical trial’s success.”

drug360 graph contains proprietary data on 180 million relationships between diseases, genes, gene variants, phenotypes, and other biomedical entities. This data is generated by tellic’s patent-pending deep learning algorithms, which scan biomedical text to extract entities, normalize them to the desired concept within biomedical ontologies, and quantify the strength of relationships. Quantifying the strength of these relationships is crucial, because it helps remove the “noise” from the signal. “tellic’s proprietary deep learning technologies incorporate biomedical context which results in high quality genetic evidence data that can improve clinical trial success,” says Wendell.

With drug360 graph, researchers can:

  • Immediately be up and running with a biomedical knowledge graph pre-populated with 180 million genetic relationships
  • Easily import their internal data into tellic’s proprietary data to create a Knowledge Graph that is unique to their organization
  • Quickly identify unexpected genetic linkages to inform target selection, clinical trial design, BD and biotech investment decisions.
  • Drill down and search genetic relationships of interest to pinpoint each sentence in the source data that was used to generate the relationship
  • Export search results into a CSV or Excel for further analysis

drug360 currently contains millions of additional relationships between genes or gene variants than those found in public databases. Available as software as a service, the product is easy to use and is well supported.

About tellic
Big data, machine learning, and natural language processing are brought together by tellic into drug360 to form a single, unparalleled source of clear-cut insights about associations between genes and diseases. The company was founded in 2015 by Richard Wendell, a Fortune 500 Chief Data Officer, whose vision was to make it easy for pharma companies to apply emerging data science technologies to their pipelines. tellic pioneers a new category of enterprise-scale biomedical language processing and knowledge discovery powered by machine learning. For more information or to arrange a demo of drug360 graph, please contact

Additional Contact:
Ryan Leventhal
VP, Business Development
Direct: 212-221-8612
SOURCE: tellic

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
2. IntelliCyt Launches iQue® Screener PLUS to Accelerate Suspension-cell Screening and Combinatorial Profiling for Immunological Applications
3. Genedata and IntelliCyt Forge Alliance to Transform Cell-based Screening in Drug Discovery
4. SpectraGenetics Joins IntelliCyt’s Technology Alliance Partner Program
5. IntelliCyt Corporation Completes $7.4 Million in New Financing
6. IntelliCyt and FIMM Announce a Collaboration to Advance Personalized Medicine in Cancer Treatment
7. AstraZeneca Enters into an Agreement with IntelliCyt for the Development of High Throughput Biology Applications
8. Massachusetts General Hospital Enters Into a Technology Alliance Partnership with IntelliCyt for the Development of CRISPR Functional Screening Applications
9. IntelliCyt Announces a New Addition to the iQue® Screener PLUS Platform During CYTO 2016
10. Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized Medicine Platform for Cancer Patients
11. IntelliCyt Launches Novel Assay System to Accelerate Cell Line Development
Post Your Comments:
(Date:5/15/2020)... ... May 14, 2020 , ... Children with defective heart valves ... before becoming adults. The reason: there are no heart valve prosthetics designed to ... Department of Defense has awarded Draper, Boston Children’s Hospital and Seattle Children’s Research ...
(Date:5/15/2020)... ... May 15, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing ... Chairman. Mr. Ganz will continue to lead Sentien’s Board of Directors, a role ... CEO Brian Miller and Sentien’s management team. , Mr. Ganz has more ...
(Date:5/14/2020)... YORBA LINDA, Calif. (PRWEB) , ... May 12, ... ... of life science tools for translational research, is bringing together thousands of industry ... , The scientific program highlights two plenary speakers, Carl June, MD, Director of ...
(Date:5/14/2020)... TORONTO (PRWEB) , ... May 13, 2020 , ... ... simple reporter assays or phenotypic readouts, providing little or no information on the ... enable a more comprehensive characterization of compounds by measuring the activity of molecular ...
Breaking Biology Technology:
(Date:6/13/2020)... ... June 11, 2020 , ... Bode ... expansion of its forensic genealogy team. Bode’s Forensic Genealogy Service (FGS) ... genealogy and DNA analysis methods. The team has added experienced genealogists, each having ...
(Date:6/11/2020)... ... June 09, 2020 , ... Superior Controls, Inc. , an E ... solutions for the life sciences industry, is pleased to announce the recent hiring of ... the company’s Seabrook, New Hampshire office. In his new role, Boudreau will use ...
(Date:6/5/2020)... ... 2020 , ... “Although we are disappointed to have to make this decision ... the public. We remain committed to creating a global platform to showcase the ... Sutcliffe, President of WMIS. , The abstract deadline for the virtual ...
Breaking Biology News(10 mins):